New hope for kidney patients: dapagliflozin trial targets slowing disease
NCT ID NCT06610526
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing the drug dapagliflozin in 731 Chinese adults with chronic kidney disease. The goal is to see if the drug can slow kidney decline and is safe. Participants take the drug by mouth, and researchers track kidney function and side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin (a drug taken by mouth that helps protect the kidneys)
What this could lead to
If it works, this could provide a new treatment option to slow kidney disease progression in Chinese patients.
What could go wrong
This is a single-arm, open-label study without a placebo group, so results may be less reliable. It is also limited to Chinese adults, so findings may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100034, China
-
Research Site
Beijing, 100044, China
-
Research Site
Beijing, 100068, China
-
Research Site
Beijing, 100191, China
-
Research Site
Beijing, 102206, China
-
Research Site
Changchun, 130021, China
-
Research Site
Dongguan, 523059, China
-
Research Site
Foshan, 528308, China
-
Research Site
Fuyang, 236012, China
-
Research Site
Fuzhou, 350001, China
-
Research Site
Ganzhou, 341099, China
-
Research Site
Harbin, 150000, China
-
Research Site
Hefei, 230601, China
-
Research Site
Hengyang, 421001, China
-
Research Site
Huaian, 223399, China
-
Research Site
Huizhou, 516001, China
-
Research Site
Jilin City, 132011, China
-
Research Site
Jinan, 250014, China
-
Research Site
Jining, 272029, China
-
Research Site
Lanzhou, 730000, China
-
Research Site
Linyi, 276199, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Nanjing, 210029, China
-
Research Site
Nanning, 530021, China
-
Research Site
Ningbo, 315010, China
-
Research Site
Shanghai, 200090, China
-
Research Site
Shenzhen, 518036, China
-
Research Site
Suzhou, 215004, China
-
Research Site
Taian, 271099, China
-
Research Site
Tianjin, 300121, China
-
Research Site
Wuhu, 241000, China
-
Research Site
Wuxi, 214023, China
-
Research Site
Xi'an, 710000, China
-
Research Site
Xiamen, 361004, China